Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NXTC

NXTC - NextCure Inc Stock Price, Fair Value and News

$10.81-0.31 (-2.79%)
Market Closed

Price Targets

NXTC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NXTC Price Action

Last 7 days

-16.8%

Last 30 days

-18.2%

Last 90 days

-11.8%

Trailing 12 Months

12.7%

NXTC RSI Chart

NXTC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NXTC Valuation

Market Cap

29.0M

Price/Earnings (Trailing)

-0.5

Price/Sales (Trailing)

1.15

Price/Free Cashflow

-0.59

NXTC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

NXTC Fundamentals

NXTC Revenue

Revenue (TTM)

22.4M

NXTC Earnings

Earnings (TTM)

-58.0M

Earnings Growth (Yr)

25.27%

Earnings Growth (Qtr)

67.83%

NXTC Profitability

Return on Equity

-245.33%

Return on Assets

-146.44%

Free Cashflow Yield

-168.95%

NXTC Investor Care

Shares Dilution (1Y)

14.82%

Diluted EPS (TTM)

-24.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202027.4M26.0M24.4M22.4M
20190006.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About NextCure Inc

NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
 CEO
 WEBSITEnextcure.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES99

NextCure Inc Frequently Asked Questions

NXTC is the stock ticker symbol of NextCure Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of NextCure Inc is 28.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NXTC's fair value in chart for subscribers.

The fair value guage provides a quick view whether NXTC is over valued or under valued. Whether NextCure Inc is cheap or expensive depends on the assumptions which impact NextCure Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NXTC.

As of Wed Jan 28 2026, NXTC's PE ratio (Price to Earnings) is -0.5 and Price to Sales (PS) ratio is 1.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NXTC PE ratio will change depending on the future growth rate expectations of investors.